Asia-Pacific DNA Vaccines Market 2019-2027

Market Outlook

The Asia-Pacific DNA vaccines market is expected to make progressive growth at a CAGR of 42.79% in terms of revenue throughout the estimated period of 2019-2027. Japan, India, China, South Korea, Australia & New Zealand, ASEAN countries and countries in rest of APAC together constitute the market for DNA vaccines in the Asia-Pacific region. The DNA vaccines market in China is mainly driven by the growing investments by the government of China for clinical trials and development of DNA vaccines towards the treatment of chronic diseases such as cancer, HPV, diabetes, etc. In March 2015, China’s Ministry of Science and Technology introduced a nationwide precision medicine-driven health program with an approximate investment of $9.2 billion over the forthcoming 15 years, starting in 2016 and ending by 2030. The near-term objective was to bring the precision medicine concept into normal prevention procedure that included DNA-based vaccination for chronic disease prevention, such as cerebrovascular, cardiovascular and metabolic diseases, cancer, etc. The final objective of this health investment program was aimed at enhancing the prevention capabilities of diseases, while simultaneously developing improved therapeutics depending upon the latest DNA-based translational research. These were directed towards achieving enhanced results in the country’s public health management program. There is an ongoing research for the development of DNA vaccines for the successful prevention of mucopolysaccharidosis, maxillomandibular advancement, narcissistic personality disorder, etc. in Shanghai and Beijing.

Competitive Outlook
The important players include Astellas Pharma, Inc., Dendreon Corporation (acquired by Sanpower Group), Eli Lilly and Company, Eurogentec S.A., GlaxoSmithKline, Inc., Inovio Pharmaceuticals, Inc. and Madison Vaccines, Incorporated (MVI).

1. Asia-Pacific DNA Vaccines Market - Summary

2. Industry Outlook

2.1. Market Definition
2.2. Porter's Five Forces Outlook
2.2.1. Threat of New Entrants
2.2.2. Threats of Substitute Product
2.2.3. Bargaining Power of Buyer
2.2.4. Bargaining Power of Supplier
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Value Chain Outlook
2.5. Key Insights
2.6. Regulatory Framework
2.7. Key Buying Outlook
2.8. Market Drivers
2.8.1. Surge in New Vaccine Development
2.8.2. Rise in the Usage of DNA Vaccines for Animal Healthcare
2.8.3. Rising Prevalence of Chronic and Infectious Diseases
2.9. Market Restraints
2.9.1. Lack of Legal and Ethical Framework
2.9.2. Stringent Government Regulations
2.10. Market Opportunities
2.10.1. Growing Demand for Gene Therapy
2.10.2. Steady Vaccines Are Easy to Store and Transport
2.10.3. Increasing Number of Clinical Trials on Humans
2.11. Market Challenges
2.11.1. Variation in the Regulatory Pathway and the Points of Consideration Regarding Environmental Valuation

3. DNA Vaccines Market Outlook - by Type

3.1. Animal DNA Vaccine
3.2. Human DNA Vaccine

4. DNA Vaccines Market Outlook - by Application

4.1. Human Disease
4.2. Veterinary Disease

5. DNA Vaccines Market Outlook - by Technology

5.1. Plasmid DNA Vaccines
5.2. Plasmid DNA Delivery

6. DNA Vaccines Market Outlook - by Region

6.1. Asia-Pacific
6.1.1. Country Analysis
6.1.1.1. India
6.1.1.2. China
6.1.1.3. Japan
6.1.1.4. Australia & New Zealand
6.1.1.5. South Korea
6.1.1.6. Asean Countries
6.1.1.7. Rest of Asia-Pacific

7. Competitive Landscape

7.1. Astellas Pharma, Inc.
7.2. Dendreon Corporation (Acquired by Sanpower Group)
7.3. Eli Lilly and Company
7.4. Eurogentec S.A.
7.5. Glaxosmithkline, Inc.
7.6. Inovio Pharmaceuticals, Inc.
7.7. Madison Vaccines, Incorporated (Mvi)
7.8. Merck & Co.
7.9. Merial Limited (Acquired by Boehringer Ingelheim)
7.10. Novartis AG
7.11. Sanofi
7.12. Vgxi
7.13. Vical, Incorporated
7.14. Xenetic Biosciences, Inc.
7.15. Zoetis, Inc.

8. Methodology & Scope

8.1. Research Scope
8.2. Sources of Data
8.3. Research Methodology

List of Tables

Table 1 Asia-Pacific DNA Vaccines Market 2019-2027 ($ Million)
Table 2 Intervention and Phase of Some Diseases/Conditions
Table 3 Regulations to Follow Before Commercialization
Table 4 Temperature Requirement in Preservation for Various Vaccines
Table 5 Approaches Being Tested to Enhance the Low Immunogenicity
Table 6 Clinical Trials on Humans Involving DNA Vaccines
Table 7 Asia-Pacific DNA Vaccines Market by Type 2019-2027 ($ Million)
Table 8 Asia-Pacific DNA Vaccines Market by Application 2019-2027 ($ Million)
Table 9 Asia-Pacific DNA Vaccines Market by Technology 2019-2027 ($ Million)
Table 10 Asia-Pacific DNA Vaccines Market by Country 2019-2027 ($ Million)

List of Figures

Figure 1 Asia-Pacific DNA Vaccines Market 2019-2027 ($ Million)
Figure 2 Value Chain Analysis for DNA Vaccine Industry
Figure 3 Asia-Pacific DNA Vaccines Market in Veterinary Diseases 2019-2027 ($ Million)
Figure 4 Clinical Trials of Gene Therapy
Figure 5 Asia-Pacific DNA Vaccines Market in Animal DNA Vaccines 2019-2027 ($ Million)
Figure 6 Asia-Pacific DNA Vaccines Market in Human DNA Vaccines 2019-2027 ($ Million)
Figure 7 Asia-Pacific DNA Vaccines Market Share by Application 2018 & 2026 (%)
Figure 8 Asia-Pacific DNA Vaccines Market in Human Diseases 2019-2027 ($ Million)
Figure 9 Asia-Pacific DNA Vaccines Market in Veterinary Diseases 2019-2027 ($ Million)
Figure 10 Asia-Pacific DNA Vaccines Market in Plasmid DNA Vaccines Technology 2019-2027 ($ Million)
Figure 11 Asia-Pacific DNA Vaccines Market in Plasmid DNA Delivery Technology 2019-2027 ($ Million)
Figure 12 India DNA Vaccines Market 2019-2027 ($ Million)
Figure 13 China DNA Vaccines Market 2019-2027 ($ Million)
Figure 14 Japan DNA Vaccines Market 2019-2027 ($ Million)
Figure 15 Australia & New Zealand DNA Vaccines Market 2019-2027 ($ Million)
Figure 16 South Korea DNA Vaccines Market 2019-2027 ($ Million)
Figure 17 Asean Countries DNA Vaccines Market 2019-2027 ($ Million)
Figure 18 Rest of Asia-Pacific DNA Vaccines Market 2019-2027 ($ Million)